Clinical trial
Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09%…
NCT00469690 · Innovative Medical, Industry · Completed
Key facts
| NCT number | NCT00469690 |
|---|---|
| Title | Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects |
| Official title | Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects |
| Lead sponsor | Innovative Medical, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cataract |
| Intervention type | Drug |
| Interventions | Acular, Xibrom |
| Enrollment | 58 |
| Start date | May 1, 2007 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | May 4, 2007 |
| Last update posted | May 20, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: